Roivant Sciences (ROIV) Stock Price, News & Analysis

Company Overview

Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with serious or underserved diseases. The company operates through a network of subsidiary companies, known as “Vants,” each dedicated to specific therapeutic areas, drug candidates or commercial opportunities.

Roivant’s research and development activities have included treatments for immune-mediated diseases, rare disorders, oncology and conditions affecting the nervous system. Its portfolio has included investigational therapies such as batoclimab, an antibody being studied in several autoimmune conditions, and brepocitinib, an immunomodulatory therapy evaluated for inflammatory and autoimmune diseases. The company has also pursued strategic partnerships, acquisitions and licensing transactions to advance or commercialize drug candidates.

Founded in 2014, Roivant is headquartered in Basel, Switzerland, and maintains operations in the United States and other international markets. Matt Gline has served as the company’s chief executive officer since 2021. Roivant has historically used subsidiary companies and collaborations with larger pharmaceutical businesses to develop medicines and expand their potential commercial reach.

Key Stats

• Today's Range: $34.15 to $35.59
• 50-Day Range: $33.32 to $41.81
• 52-Week Range: $15.90 to $42.50
• Volume: 5.53 million shs
• Average Volume: 7.61 million shs
• Market Capitalization: $25.60 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.64
• Consensus Rating: Moderate Buy

Roivant Sciences Stock Analysis - MarketRank™

Roivant Sciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 278th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Roivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 10 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Roivant Sciences has a consensus price target of $45.64, representing about 28.8% upside from its current price of $35.44.

Amount of Analyst Coverage

Roivant Sciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Roivant Sciences are expected to decrease in the coming year, from ($2.00) to ($2.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Roivant Sciences is -66.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Roivant Sciences is -66.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Roivant Sciences has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.97% of the float of Roivant Sciences has been sold short.

Short Interest Ratio / Days to Cover

Roivant Sciences has a short interest ratio ("days to cover") of 4.43.

Change versus previous month

Short interest in Roivant Sciences has recently increased by 8.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Roivant Sciences does not currently pay a dividend.

Dividend Growth

Roivant Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.64

News Sentiment

Roivant Sciences has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Roivant Sciences this week, compared to 5 articles on an average week.

Search Interest

Only 5 people have searched for ROIV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

6 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $58,826,636.00 in company stock.

Percentage Held by Insiders

8.80% of the stock of Roivant Sciences is held by insiders.

Percentage Held by Institutions

64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/09/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ROIV
• CIK: 1635088
• Web: roivant.com
• Phone: 44-20-7400-3347
• Fax: N/A
• Employees: 721
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Roivant Sciences: $45.64
• High Price Target: $55.00
• Low Price Target: $33.00
• Potential Upside/Downside: +28.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$299.77 million
• Net Margins: -3,534.96%
• Pretax Margin: -3,848.65%
• Return on Equity: -22.94%
• Return on Assets: -21.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.72
• Quick Ratio: 16.72

Sales & Book Value

• Annual Sales: $7.53 million
• Price / Sales: 3,398.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.35 per share
• Price / Book: 4.82

Miscellaneous

• Outstanding Shares: 722,323,000
• Free Float: 658,759,000
• Market Cap: $25.60 billion
• Optionable: Optionable
• Beta: 1.10